Microsoft word - 7h - the biphosphonates delusion.doc

The first publications about biphosphonates, which were initially named diphosphonates, were available in
1969, now more than 40 years ago. Biphosphonates are internalized by osteoclasts where they interfere with
specific biochemical pathways (Russell, 2011). They enhance osteoclasts apoptosis and they inhibit osteoclasts
attachment to the bone matrix (Dominguez et al., 2011). They are therefore used for the treatment of fragility
fractures due to post-menopausal and male osteoporosis, plus also in the case of glucocorticoid side effects,
Paget's bone disease and bone metastasis (Dominguez et al., 2011). They can be classified between nitrogen-
containing (such as alendronate or risedronate) and non-nitrogen-containing (such as etidronate or clodronate).
Bisophosphonates have become the most popular treatment for post-menopausal osteoporosis and their use has
risen continuously since their introduction in the 1990s (Hollick and Reid, 2011). Adverse inflammatory side
effects are common, especially esophageal irritation and gastro-intestinal reactions, but also cutaneous reactions,
ocular side effects, and acute phase reactions in the case of intravenous administration (Hollick and Reid, 2011).
More recently, reports of serious side effects have prompted concerns about the long-term use of biphosphonates.
Risedronate and even more notably alendronate use is linked to what are called atypical subtrochanteric fractures and femoral shaft fractures, both linked to bone insufficiency (Angthong and Angthong, 2011). More worrying is the fact that a longer duration of the biphosphonate treatment increases the odds of insufficiency fractures (Meier et al., 2012), which certainly raises concerns about how long the patients should be taking these drugs. Other side effects confirm that bone solidity does not necessarily reflect bone density. "Dental practitioners should be aware of the increased risk of implant failure associated with oral biphosphonate use in the population" (Yip et al., 2012). Practically speaking, it is well known that many dentists specializing in dental implants do not accept patients following these biphosphonate treatments due to the excessive risk of implant failure. Another concern lies in the association between biphosphonate use and jaw osteonecrosis (Arrain and Masud, 2011). Besides, it appears that patients in need of operative fixation of biphosphonate-associated femur fractures have higher complication rates than their usual femur fractures counterparts (Prasarn et al., 2012). Interestingly, among 43 retrospectively reviewed patients compared with 20 controls, "the biphosphonate cohort had a higher rate of intraoperative fractures (21% versus 0%) and postoperative plate fractures (30% versus 0%) (Prasarn et al., 2012). It is worth mentioning that biphosphonates use cannot be recommended for chronic kidney disease patients suffering from osteopenia/osteoporosis due to the risk of adynamic bone disease (Amerling et al., 2010). More classic and the object of several published reports are inflammatory ocular side effects such as uveitis and scleritis. Odds ratio approximate 1.5 for both conditions (Etminan et al., 2012). Common symptoms seen in this type of orbital inflammation include pain, diplopia, and blurry vision (Peterson and Bedrossian, 2012). Other severe side effects of long-term biphosphonate use are subject to some controversy but they have been discussed in useful reviews. Esophageal irritation represents a frequent complication of such treatments, with increasing concerns about a potential link with esophageal cancer, even if strict casualty is indeed difficult to demonstrate (Haber and McNatty, 2012). Once again, the length of biphosphonate administration could be the issue, as with another controversial severe side effect consisting in atrial fibrillation (Sewerynek & Stuss, 2011). In conclusion, we should mention a recent review of the most relevant articles reporting serious adverse effects of biphosphonates. "Biphosphonates reduce vertebral fractures in short-term use while in long-term can cause osteonecrosis [of the] jaw, esophageal cancer, atrial fibrillation, and increase the risk of atypical fractures and probably adynamic bone disease" (Salari and Abdollahi, 2012). We can only share the conclusion of these authors, i.e. that prescribers should "consider full assessment of risk-benefit and the duration of treatment". Amerling R, Harbord NB, Pullman J, Feinfeld DA. 2010. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29:293-299. Angthong C, Angthong W. 2011. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. J Med Assoc Thai 94 Suppl 7:S214-220. Arrain Y, Masud T. 2011. A current update on osteonecrosis of the jaw and bisphosphonates. Dent Update 38:672-676, 678. Dominguez LJ, Di Bella G, Belvedere M, Barbagallo M. 2011. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 12:397-408. Etminan M, Forooghian F, Maberley D. 2012. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ 184:E431-434. Haber SL, McNatty D. 2012. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann Hollick RJ, Reid DM. 2011. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int 17:66-72. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. 2012. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172:930-936. Peterson JD, Bedrossian EH, Jr. 2012. Bisphosphonate-associated orbital inflammation--a case report and review. Orbit Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. 2012. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res 470:2295-2301. Russell RG. 2011. Bisphosphonates: the first 40 years. Bone 49:2-19. Salari P, Abdollahi M. 2012. Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back. J Pharm Sewerynek E, Stuss M. 2011. [Bisphosphonates and the risk of atrial fibrillation]. Endokrynol Pol 62 Suppl 3:10-13. Yip JK, Borrell LN, Cho SC, Francisco H, Tarnow DP. 2012. Association between oral bisphosphonate use and dental implant failure among middle-aged women. J Clin Periodontol 39:408-414.


Microsoft word - hypothyroidism study guide and acknowledgement form.doc

THE GULF COAST CENTER ACKNOWLEDGEMENT OF RECEIPT & UNDERSTANDING OF HYPOTHYROIDISM TRAINING MATERIAL I acknowledge that I have received a copy of Training Material on Hypothyroidism, and I acknowledge that I have read and understand its contents. Please mail completed form to this address after completion: The Gulf Coast Center Attention: Lina Ellis P.O. Box 2490 Galveston, TX

Corporates Pharmaceuticals Cipla Limited Full Rating Report Key Rating Drivers Comfortable Leverage: India Ratings & Research (Ind-Ra) assigned Cipla Limited’s (Cipla) INR10,000m commercial paper/short-term debt programme a Short-Term Rating of ‘IND A1+’ on 29 April 2013. The rating reflects Cipla’s low leverage (adjusted debt net of cash/EBITDAR) of below

Copyright © 2010 Health Drug Pdf